Insmed (INSM) Soars 33.86% as Brinsupri Drives Fourfold Growth. Here’s What to Watch Next

Insmed (NASDAQ:INSM) saw its share price increase by 33.86 percent on Thursday to close at $132.55 apiece after nearly quadrupling its revenues in the second quarter of the year, thanks to a strong uptake from its treatment for non-cystic fibrosis bronchiectasis (NCFB).

In an updated report, the company said that total revenues soared by 296 percent during the period to $425.5 million from only $107.4 million in the same period last year, on the back of a $309.2 million share from its drug, Brinsupri.

On the other hand, its lung disease treatment, Arikayce, contributed $116.3 million in revenues, up 8 percent from $107.4 million year-on-year.

The strong performance helped the company slash its net loss in the same period of the year by 96 percent to only $13.2 million from the $321.7 million loss in the same comparable period.

First-half net loss also shrank by 69 percent to $176.8 million from $578.3 million year-on-year, signaling that its accelerating revenues are translating into operating leverage.

Encouraged by the strong results, Insmed (NASDAQ:INSM) raised its revenue growth guidance for the full-year period to a range of $1.25 billion to $1.4 billion, or an implied jump of 624 percent to 710.6 percent from the $172.7 million year-on-year,

On the other hand, its MAC lung disease therapy, Arikayce, is expected to rake in $450 million to $470 million, or a targeted 3.7 percent to 8 percent jump from the $433.8 million in the same comparable period.

Looking ahead, investors are expected to closely watch whether Brinsupri could sustain its strong momentum, while expanding Arikayce into additional markets, including Japan. The company is also awaiting a decision for brensocatib as a treatment for NCFB in Japan in the second half of 2026.